Treatment of Wilson's disease with zinc: XV long-term follow-up studies

Journal of Laboratory and Clinical Medicine

Volumn 132, Issue 4, 1998, Pages 264-278

  Brewer, George J ^a   Dick, Robert D ^a   Johnson, Virginia D ^a   Brunberg, James A ^a   Kluin, Karen J ^a   Fink, John K ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0032191253     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(98)90039-7     Document Type: Article

References (53)

1. Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine 1992;3:139-64.
2. Scheinberg IH, Sternlieb I. Wilson's disease. In: Smith LH Jr, editor. Major problems in internal medicine (vol 23). Philadelphia: WB Saunders Co; 1984.
3. Cartwright GE, Wintrobe MM. Copper metabolism in normal subjects. Am J Clin Nutr 1964;14:224-32.
4. Bush JA, Mahoney JP, Markowitz H, Gubler CJ, Cartwright GE, Wintrobe MM. Studies on copper metabolism. XVI. Radioactive copper studies in normal subjects and in patients with hepatolenticular degeneration. J Clin Invest 1955;34:1766-78.
5. Frommer DJ. Defective biliary excretion of copper in Wilson's disease. Gut 1974;15:125-9.
6. O'Reilly S, Weber PM, Oswald M, Shipley L. Abnormalities of the physiology of copper in Wilson's disease. III. The excretion of copper. Arch Neurol 1071;25:28-32.
7. Gibbs K, Walshe JM. Biliary excretion of copper in Wilson's disease. Lancet 1980;2:538-9.
8. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nature Genet 1993;5:327-37.
9. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nature Genet 1993;5:44-50.
10. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun 1993;197:271-7.
11. Starosta-Rubenstein S, Young AB, Kluin K, Hill G, Aisen AM, Gabrielsen T, et al. Clinical assessment of 31 patients with Wilson's disease: correlations with structural changes on magnetic resonance imaging. Arch Neurol 1987;44:365-70.
12. Akil M, Schwartz JA, Dutchak D, Yuzbasiyan-Gurkan V, Brewer GJ. The psychiatric presentations of Wilson's disease. J Neuropsychiatry 1991;3:377-82.
13. Sternlieb I, Scheinberg IH. Prevention of Wilson's disease in asymptomatic patients. N Engl J Med 1968;278:352-9.
14. Brewer GJ, Yuzbasiyan-Gurkan V, Lee D-Y, Appelman H. The Treatment of Wilson's disease with zinc: VI. Initial treatment studies. J Lab Clin Med 1989;114:6333-8.
15. Walshe JM. Penicillamine. A new oral therapy for Wilson's disease. Am J Med 1956;21:487-95.
16. Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1982;1:643-7.
17. Hoogenraad TU, Koevoet R, De Ruyter Korver EGWM. Oral zinc sulfate as long-term treatment in Wilson's disease (hepatolenticular degeneration). Eur Neurol 1979;18:205-11.
18. Hoogenraad TU, Van den Hammer CJA, Koevoet R, De Ruyter Korver EGWM. Oral zinc in Wilson's disease. Lancet 1978;2:1262-3.
19. Hoogenraad TU, Van Hattum J, Van den Hammer CJA. Management of Wilson's disease with zinc sulfate. Experience in a series of 27 patients. J Neurol Sci 1987;77:137-46.
20. Brewer GJ, Hill GM, Prasad AS, Cossack ZT, Rabbani P. Oral zinc therapy for Wilson's disease. Ann Intern Med 1983;99:314-20.
21. Hill GM, Brewer GJ, Prasad AS, Hydrick CR, Hartmann DE. Treatment of Wilson's disease with zinc: I. Oral zinc therapy regimens. Hepatology 1987;7:522-8.
22. 64Cu uptake with copper balance. Am J Med Sci 1986;12:344-9.
23. Brewer GJ, Hill GM, Dick RD, Nostrant TT, Sams JS, Wells JJ, et al. Treatment of Wilson's disease with zinc: III. Prevention of reaccumulation of hepatic copper. J Lab Clin Med 1987;109:526-31.
24. Brewer GJ, Hill GM, Prasad AS, Dick RD. Treatment of Wilson's disease with zinc: IV. Efficacy monitoring using urine and plasma copper. Proc Soc Exp Biol Med 1987;7:446-55.
25. Yuzbasiyan-Gurkan V, Brewer GJ, Abrams GD, Main B, Giacherio D. Treatment of Wilson's disease with zinc: V. Changes in serum levels of lipase, amylase, and alkaline phosphatase in Wilson's disease patients. J Lab Clin Med 1989;114:520-6.
26. Lee D-Y, Brewer GJ, Wang Y. The treatment of Wilson's disease with zinc: VII. Protection of the liver from copper toxicity by zinc-induced metallothionein in a rat model. J Lab Clin Med 1989;114:639-45.
27. Brewer GJ, Yuzbasiyan-Gurkan V, Dick R. Zinc therapy of Wilson's disease: VIII. Dose response studies. Trace Elements in Experimental Medicine 1990;3:227-34.
28. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V. The treatment of Wilson's disease with zinc: IX. Response of serum lipids. J Lab Clin Med 1991;118:466-70.
29. Yuzbasiyan-Gurkan V, Brider A, Nostrant T, Cousins RJ, Brewer GJ. The treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med 1992;120:380-6.
30. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents. J Am Coll Nutr 1993;12:26-30.
31. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc: XII. Dose regimen requirements. Am J Med Sci 1993;305:199-202.
32. Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Johnson V, Wang Y. Treatment of Wilson's disease with zinc: XIII. Therapy with zinc in presymptomatic patients from the time of diagnosis. J Lab Clin Med 1994;123:849-58.
33. Brewer GJ, Kaplan J, Johnson V. The treatment of Wilson's disease with zinc: XIV. Studies of the effect of zinc on lymphocyte function. J Lab Clin Med 1997;129:649-52.
34. Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Tankanow R, Young AB, Kluin KJ. Initial therapy of Wilson's disease patients with tetrathiomolybdate. Arch Neurol 1991;48:42-7.
35. Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkan V, Kluin K, et al. Treatment of Wilson's disease with tetrathiomolybdate: I. Initial therapy in 17 neurologically affected patients. Arch Neur 1994;51:545-54.
36. Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA. Treatment of Wilson's disease with ammonium tetrathiomolybdate: II. Initial therapy in 33 neurologically affected patients and follow-up on zinc therapy. Arch Neurol 1996;53:1017-25.
37. Czlonkowska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate. J Neurol 1996;243:269-73.
38. Scheinberg IH, Sternlieb I, Schilsky M, Stockert RJ. Penicillamine may detoxify copper in Wilson's disease. Lancet 1987;2:95.
39. Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987;44:490-3.
40. Black MR, Medeiros DM, Bruneti E, Welke R. Zinc supplements and serum lipids in young adult white males. Am J Clin Nutr 1988;47:970-5.
41. Chandra RK. Excessive intake of zinc impairs immune responses. JAMA 1984;252:1443-6.
42. Hooper PL, Visconti L, Garry PJ, Johnson GE. Zinc lowers high-density lipoprotein-cholesterol levels. JAMA 1980;244:1960-1.
43. Lee HH, Hill GM, Murthy Sikha VKN, Brewer GJ, Prasad AS, Owyang C. Pancreaticobiliary secretion of zinc and copper in normal persons and patients with Wilson's disease. J Lab Clin Med 1990;116:283-8.
44. Brewer GJ, Feitler Brewer L, Prasad AS. Suppression of irreversibly sickled erythrocytes by zinc therapy in sickle cell anemia. J Lab Clin Med 1977;90:549-54.
45. Brewer GJ, Schoomaker EB, Leichtman DA, Kruckeberg WC, Brewer LF, Meyers N. The use of pharmacological doses of zinc in the treatment of sickle cell anemia. In: Brewer GJ, Prasad AS, editors. Zinc metabolism: current aspects in health and disease. New York: Alan R. Liss Inc.; 1987. p. 241-54.
46. Shimon I, Sela BA, Moses B, Doley E. Hemolytic episode in a patient with Wilson's disease treated with zinc. Israel J Med Sci 1993;29:646-7.
47. Walshe JM, Munro NAR. Zinc-induced deterioration in Wilson's disease aborted by treatment with penicillamine, dimercaprol, and a novel zero copper diet. Arch Neurol 1995;52:10-1.
48. Sternlieb I. Present status of diagnosis and prophylaxis of asymptomatic patients with Wilson's disease. In: Leevy CMS, editor. Diseases of the liver and biliary tract. Basel: Karger; 1976. p. 137-42.
49. Scheinberg IH, Sternlieb I. Pregnancy in penicillamine-treated patients with Wilson's disease. N Engl J Med 1975;293:1300-2.
50. Mjolnerod OK, Dommerud SA, Rasmussen K, Gjeruldsen ST. Congenital connective tissue defect probably due to D-penicillamine treatment in pregnancy. Lancet 1971;1:673-5.
51. Solomon L, Abrams G, Dinner M, Berman L. Neonatal abnormalities associated with D-penicillamine treatment during pregnancy. N Engl J Med 1977;296:54-5.
52. Keen CL, Lonnerdal B, Hurley LS. Teratogenic effect of copper deficiency and excess. In: Sorenson JRJ, editor. Inflammatory diseases and copper. Clifton, NJ: Humana Press; 1982. p. 109-21.
53. Food and Drug Administration. Teratologic evaluation of FDA 71-49 (zinc sulfate). Food and Drug Research Laboratories, Inc. Prepared for Food and Drug Administration, United States Department of Commerce Publications PD-221 805, February 1973, and PB 267, June 1974.